Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19

Yan Xie, Taeyoung Choi, Ziyad Al-Aly
doi: https://doi.org/10.1101/2022.11.03.22281783

Article Information

doi 
https://doi.org/10.1101/2022.11.03.22281783
History 
  • November 5, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Yan Xie1,2,
  2. Taeyoung Choi1,2 and
  3. Ziyad Al-Aly*,1,2,3,4,5
  1. 1Clinical Epidemiology Center, Research and Development Service, VA Saint Louis Health Care System, Saint Louis, Missouri
  2. 2Veterans Research and Education Foundation of Saint Louis, Saint Louis, Missouri
  3. 3Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri
  4. 4Nephrology Section, Medicine Service, VA Saint Louis Health Care System, Saint Louis, Missouri
  5. 5Institute for Public Health, Washington University in Saint Louis, Saint Louis, Missouri
  1. ↵*Corresponding author: Ziyad Al-Aly; email: zalaly{at}gmail.com ; Twitter: @zalaly
Back to top
Posted November 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19
Yan Xie, Taeyoung Choi, Ziyad Al-Aly
medRxiv 2022.11.03.22281783; doi: https://doi.org/10.1101/2022.11.03.22281783
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area